Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 2
2015 1
2018 1
2019 1
2021 2
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

7 results
Results by year
Filters applied: . Clear all
Page 1
Therapeutic Targeting of Checkpoint Receptors within the DNAM1 Axis.
Alteber Z, Kotturi MF, Whelan S, Ganguly S, Weyl E, Pardoll DM, Hunter J, Ophir E. Alteber Z, et al. Cancer Discov. 2021 May;11(5):1040-1051. doi: 10.1158/2159-8290.CD-20-1248. Epub 2021 Mar 9. Cancer Discov. 2021. PMID: 33687987 Free article. Review.
Mouse PVRIG Has CD8+ T Cell-Specific Coinhibitory Functions and Dampens Antitumor Immunity.
Murter B, Pan X, Ophir E, Alteber Z, Azulay M, Sen R, Levy O, Dassa L, Vaknin I, Fridman-Kfir T, Salomon R, Ravet A, Tam A, Levin D, Vaknin Y, Tatirovsky E, Machlenkin A, Pardoll D, Ganguly S. Murter B, et al. Among authors: alteber z. Cancer Immunol Res. 2019 Feb;7(2):244-256. doi: 10.1158/2326-6066.CIR-18-0460. Epub 2019 Jan 18. Cancer Immunol Res. 2019. PMID: 30659055 Free PMC article.
COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade.
Hansen K, Kumar S, Logronio K, Whelan S, Qurashi S, Cheng HY, Drake A, Tang M, Wall P, Bernados D, Leung L, Ophir E, Alteber Z, Cojocaru G, Galperin M, Frenkel M, White M, Hunter J, Liang SC, Kotturi MF. Hansen K, et al. Among authors: alteber z. Cancer Immunol Immunother. 2021 Dec;70(12):3525-3540. doi: 10.1007/s00262-021-02921-8. Epub 2021 Apr 26. Cancer Immunol Immunother. 2021. PMID: 33903974